SEQUEL
LIVE

Serial Number

97812964

Owner

DEKA Research & Development Corp.

Attorney

Mark E. Tetreault

Filing Date

Feb 27, 2023

Add to watchlist:

No watchlists yet
View on USPTO

SEQUEL Trademark

Serial Number: 97812964

SEQUEL is a trademark filed by DEKA Research & Development Corp. on February 27, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

DEKA Research & Development Corp. (30 trademarks)

340 Commercial Street
Manchester, NH 03101

Entity Type: 03

Trademark Details

Filing Date

February 27, 2023

Registration Date

Not Registered

Published for Opposition

February 27, 2024

Goods & Services

Educational services, namely, creating and developing web-based and in person classes, seminars, workshops and programs in the field of managing and living with chronic disease; personalized training and coaching in the use of monitoring devices and infusion pumps in the treatment of chronic disease; training of healthcare providers in chronic disease treatment and the use of infusion pumps and infusion sets

Software as a Medical Device (SaMD), downloadable, for predicting blood analyte levels and adjusting infusion pump settings based on personalized data for use in connection with a device for the delivery of therapeutic agents for the treatment of disease; Downloadable educational mobile applications featuring information and instruction on managing, treating and living with chronic disease; batteries; battery chargers

Infusion cartridges sold pre-filled with medication for medical use in the field of cardiovascular disease, diabetes, asthma, kidney disease, and cancer; Adhesive overlays in the nature of adhesive medical tape and adhesive bandages for use with infusion pumps and associated devices, all of the foregoing for use in connection with a device for the delivery of therapeutic agents for the treatment of disease

Providing a trade-in program for drug delivery and chronic disease management devices; Pharmaceutical services, namely, mail order pharmacy services and processing online and telephone prescription orders in retail and central fill pharmacies featuring chronic disease management supplies, medications, drugs and other prescriptions

Interactive medical monitoring and alert services for reminding infusion pump users of medicinal dosage for medical treatment purposes in the nature of monitoring and managing chronic disease; Providing medical information to infusion pump users for use in connection with a device for the delivery of therapeutic agents for the treatment of disease in the form of reports in the field of chronic disease management; Providing a website featuring general medical information related to chronic diseases, including advice on treatment options and chronic disease management; providing online searchable medical databases in the field of chronic disease management for patients, their families and caregivers, and healthcare practitioners; medical consultation services, namely, patient ambassador program to communicate medical information to people with chronic disease, all of the foregoing related to use of a device for the delivery of therapeutic agents for the treatment of disease

Medical devices, namely, infusion and injection devices for administering therapeutic agents for the treatment of disease, and pouches and mounts used therewith; medical devices, namely, infusion pumps for delivering measured amounts of solutions into the bloodstream over time for the treatment of disease; medical apparatus for monitoring blood analyte levels for use in connection with a device for the delivery of therapeutic agents for the treatment of disease; implantable subcutaneous devices for the delivery of therapeutic agents for the treatment of disease, sold empty in the nature of medical fluid injectors; on-body medical fluid injectors for the delivery of therapeutic agents for the treatment of disease; chronic disease management devices in the nature of medical sensors for use in connection with a device for the delivery of therapeutic agents for the treatment of disease that are implanted or inserted into the human body used to continuously gather human biometric data for monitoring the concentration of analytes in the human body and also including accessories therefor, namely, receivers, sensor housings and sensor insertion devices sold as a unit; medical infusion sets comprised of infusion tubing, infusion needles, needle guards, connectors, attachment clips, and accessories therefor, all used for the delivery of therapeutic agents for the treatment of disease

Software-as-a-service (SAAS) featuring software for use in the acquisition, capture, processing, presentation, transmission and storage of medical and physiological data obtained from medical sensors that are implanted or inserted into the human body; Providing an interactive web site featuring technology that enables users to enter, access, track, monitor and generate health and medical information and reports relating to managing chronic disease, medication and analyte levels; Upgrading of computer software, namely, Software as a Medical Device (SaMD) for predicting blood analyte levels and adjusting infusion pump settings based on personalized data for use in connection with a device for the delivery of therapeutic agents for the treatment of disease

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 9, 2025 EXRA
SOU EXTENSION 1 GRANTED
Aug 8, 2025 EX1G
SOU EXTENSION 1 FILED
Aug 8, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 8, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 18, 2025 NOAM
TTAB RELEASE CASE TO TRADEMARKS
Feb 3, 2025 TMBN
OPPOSITION TERMINATED NO. 999999
Feb 3, 2025 OP.T
OPPOSITION DISMISSED NO. 999999
Feb 3, 2025 OP.D
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Aug 26, 2024 ETOP
OPPOSITION INSTITUTED NO. 999999
Aug 26, 2024 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
Mar 23, 2024 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 4, 2024 NPUB
PUBLISHED FOR OPPOSITION
Feb 27, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 7, 2024 NONP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 7, 2024 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 24, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 24, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 24, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 24, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 24, 2024 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jan 24, 2024 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Dec 19, 2023 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 5, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 30, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 30, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 30, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 29, 2023 GNRN
NON-FINAL ACTION E-MAILED
Nov 29, 2023 GNRT
NON-FINAL ACTION WRITTEN
Nov 29, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 28, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 16, 2023 NWOS
NEW APPLICATION ENTERED
Mar 2, 2023 NWAP